Lulu Sun, MD, PhD

Medical School Department Pathology and Immunology
Research Program Breast Cancer Research
Lulu Sun

Researcher Background

Primary Academic Title

Assistant Professor of Pathology and Immunology, WashU Medicine

Training

  • 2016 - 2020: Resident, Anatomic Pathology, Washington University, St. Louis, MO
  • 2018 - 2019: Fellow, Molecular Genetic Pathology, Washington University, St. Louis, MO
  • 2020 - 2021: Fellow, Gynecologic and Breast Pathology, Washington University, St. Louis, MO

Education

  • 2016: MD, Washington University, St. Louis, MO
  • 2016: PhD, Immunology, Washington University, St. Louis, MO

Research & Selected Publications

Research Publications

Spatial transcriptomic landscape of invasion patterns in human papillomavirus-associated endocervical adenocarcinoma.
Authors:

Axelrod ML, Zhou R, Sun L

Journal & Year:

Sci Rep • 2026

Morphologic Correlations With Homologous Recombination Deficiency in High-grade Serous Carcinomas.
Authors:

Chapagain U, Huecker JB, Sun L

Journal & Year:

Int J Gynecol Pathol • 2025

Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer.
Authors:

Schab A, Compadre A, Drexler R, one or more additional authors omitted Sun L, one or more additional authors omitted Mullen MM

Journal & Year:

J Clin Invest • 2025

Catching Up to Increased Complexity in Breast Cancer Molecular Testing.
Authors:

Bean GR, Lin CY, Krystel-Whittemore M, Sun L

Journal & Year:

J Mol Diagn • 2025

A Pulmonary Nodule with an Unexpected Mutation Profile.
Authors:

Sun L, Krigman HR, Rohatgi A, Ansstas G , Hughes AEO

Journal & Year:

Clin Chem • 2025

A fully next-generation sequencing-based method of classifying molecular sub-types of endometrial cancer retains prognostic value and expands biomarker targets.
Authors:

Valentine MC, Wong A, Chen L, one or more additional authors omitted Sun L

Journal & Year:

Int J Gynecol Cancer • 2025

Spatial Mapping of Hematopoietic Clones in Human Bone Marrow.
Authors:

Young AL, Davis HC, Cox MJ, one or more additional authors omitted Sun L, one or more additional authors omitted Challen GA

Journal & Year:

Blood Cancer Discov • 2024

SCCA1/SERPINB3 suppresses antitumor immunity and blunts therapy-induced T cell responses via STAT-dependent chemokine production.
Authors:

Chen L, Shi V, Wang S, Sun L, one or more additional authors omitted Markovina S

Journal & Year:

J Clin Invest • 2023